{"entity":{"id":"nct07492342","kind":"trial","name":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","aka":["K-NADIR"],"tldr":"A phase 2 trial of fulzerasib in lung cancer, run by Jianxing He, now recruiting.","summary":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC is a phase 2, interventional study registered as NCT07492342 by Jianxing He, with a registry enrolment figure of 30 participants, started 2026-01-29 and due to reach its primary completion in 2027-03-31. Interventions recorded: fulzerasib. Conditions listed: Resectable NSCLC; KRAS G12C Mutation; Stage IB-IIIA NSCLC; Neoadjuvant Therapy. Primary outcome: Pathological Complete Response, pCR. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed primary non-small cell lung cancer (NSCLC)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07492342","url":"https://clinicaltrials.gov/study/NCT07492342"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["kras-g12c-nsclc","resectable-nsclc"],"sections":[],"technologies":["kras-inhibitors"],"targets":[],"drugs":["fulzerasib"],"companies":["innovent"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07492342","phase":"2","setting":"Evaluation of Efficacy and Safety of Fulzerasib Sequentially Combined With Sintilimab Plus Platinum-Doublet Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-Small Cell Lung Cancer With KRAS G12 Mutation: a Single-Arm, Phase II Clinical Trial","sponsor":"Jianxing He","participation":[{"nct":"NCT07492342","source":"https://clinicaltrials.gov/study/NCT07492342","fetchedAt":"2026-10-07T16:55:46.774Z","studySha256":"20f9cf3f1fb74af1602b806c7e478acbc244675311794b5a88011b5ae85798d2","overallStatus":"RECRUITING","lastUpdatePosted":"2026-03-25","leadSponsor":"Jianxing He","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":30,"enrolmentType":"ESTIMATED","siteCount":3,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-01-29","startedType":"actual","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07492342/","neighbours":{"cancer":[{"id":"kras-g12c-nsclc","kind":"cancer","name":"KRAS G12C-mutant non-small-cell lung cancer","route":"/cancers/kras-g12c-nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"kras-inhibitors","kind":"technology","name":"KRAS & RAS inhibitors","route":"/technologies/kras-inhibitors/"}],"drug":[{"id":"fulzerasib","kind":"drug","name":"Fulzerasib","route":"/drugs/fulzerasib/"}],"company":[{"id":"innovent","kind":"company","name":"Innovent Biologics","route":"/companies/innovent/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}